GlassScriptPhysician profile
Dragan Djordjevic
NPI 1518992783
$6,738.78
in general payments reported to CMS, 2019-2025
34 companies · $664 in 2025
The $664 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $959 · 2021: $1,315 · 2022: $1,194 · 2023: $1,018 · 2024: $478 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.69 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,626.09 | 2019-2025 | |
| Novo Nordisk INC | $921.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.54 | 2019-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $305.83 | 2019-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $303.93 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $288.22 | 2019-2023 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $282.50 | 2019-2024 | Xarelto |
| Eisai INC. | $258.43 | 2020-2024 | |
| Kowa Pharmaceuticals America, INC. | $247.28 | 2019-2021 | |
| Abbvie INC. | $246.66 | 2019-2024 | Linzess, Viberzi, Creon |
| Novartis Pharmaceuticals Corporation | $208.79 | 2019-2023 | |
| Sanofi Pasteur INC. | $157.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $133.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.97 | 2019-2024 | Xifaxan, Trulance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $106.36 | 2019-2020 | |
| Lilly USA, LLC | $106.32 | 2024-2025 | Zepbound, Mounjaro |
| Ironwood Pharmaceuticals, INC | $87.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $87.18 | 2019-2024 | Belsomra, Capvaxive |
| Glaxosmithkline, LLC. | $85.85 | 2019-2023 | Shingrix |
| Exact Sciences Corporation | $84.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $69.10 | 2021 | |
| Seqirus USA INC | $64.45 | 2024-2025 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $49.34 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $46.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $46.26 | 2023 | Strensiq |
| Redhill Biopharma INC. | $43.62 | 2020 | |
| Ibsa Pharma INC. | $34.78 | 2021 | |
| Medicure Pharma INC. | $29.23 | 2021-2022 | |
| Corcept Therapeutics | $28.87 | 2025 | Korlym |
| Radius Health, INC. | $20.07 | 2019 | |
| Alfasigma USA, INC. | $17.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.56 | 2019 | |
| Genentech USA, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dragan Djordjevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.